TNGX

TNGX

USD

Tango Therapeutics Inc.

$8.010+0.120 (1.521%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$7.890

Máximo

$8.170

Mínimo

$7.470

Volume

2.98M

Fundamentos da empresa

Capitalização de mercado

1.1B

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

2.68M

Bolsa de valores

NGM

Moeda

USD

Faixa de 52 semanas

Mínimo $1.03Atual $8.010Máximo $9.7

Notícias relacionadas

GlobeNewswire

Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S.

Ver mais
Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Analyst Upgrades

Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $12

Guggenheim analyst Charles Zhu maintains Tango Therapeutics with a Buy and raises the price target from $10 to $12.

Ver mais
Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $12
GlobeNewswire

Tango Therapeutics Announces $225 Million Financing

BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines,

Ver mais
Tango Therapeutics Announces $225 Million Financing
GlobeNewswire

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49%

Ver mais
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.